Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C

Marc C. Chamberlain, Sandra K. Johnston, Alixis Horn, Michael J. Glantz

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


Background: The most frequent central nervous system complication of systemic non-Hodgkin's lymphoma (NHL) is lymphomatous meningitis (LM). Objective: A clinical series to test the feasibility of combining intra-CSF liposomal ara-C and rituximab for the treatment of recurrent LM. Design: Clinical series of 14 patients with CSF positive lymphomatous meningitis. Setting: Tertiary-care university medical center. Results: Fourteen patients with recurrent, cytologically positive lymphomatous meningitis were treated. All 14 received liposomal ara-C and rituximab utilizing an Ommaya reservoir. Six patients also received involved-field radiotherapy (brain only two patients; brain and spine two patients; spine only two patients). Best response to treatment included 10 partial responses and four with progressive disease. Estimated median duration of response was 4.0 months (range 1-6 months). Survival ranged from 1.5 to 7 months with an estimated median of 5 months, four patients remain alive and continue to be followed. Cause of death was progressive neurological disease in 7, systemic disease in 1, and combined systemic and neurological disease in 2 patients. Conclusions: The combination of intra-CSF liposomal ara-C and rituximab administered in this schedule appears to have no additive toxicity and has modest palliative activity in patients with recurrent LM.

Original languageEnglish (US)
Pages (from-to)271-277
Number of pages7
JournalJournal of neuro-oncology
Issue number3
StatePublished - 2009

All Science Journal Classification (ASJC) codes

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research


Dive into the research topics of 'Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C'. Together they form a unique fingerprint.

Cite this